EMPAGLIFLOZIN

Product Description

is one of the biggest manufacturer, supplier, exporter and trader ofthe EMPAGLIFLOZIN finished formulationsmoreover EMPAGLIFLOZINAPI. Niksan Pharmaceutical is the huge manufacturer, exporter andsupplier of EMPAGLIFLOZINAPI and formulation situated in Ankleshwar, Gujarat, India.

NiksanPharmaceutical is the suppliers, manufacturer, exporters and trader of
EMPAGLIFLOZIN inthedomestic level as well as the international market.

 

Niksan is anIndian based pharmaceutical company so it also supplies and manufactures the EMPAGLIFLOZIN to allIndian states like Gujarat, Maharashtra, Punjab, Delhi, Tamilnadu, Goa, UttarPradesh, Karnataka, Jammu & Kashmir, West Bengal, Assam, Rajasthan, Hyderabad,Karnataka, Kerala, Madhya Pradesh, Manipur, Meghalaya, Mizoram, Nagaland,Orissa, Punjab and Haryana.  

 

NiksanPharmaceutical and Niksan group companies are exporters, suppliers andmanufacturers of the API and also EMPAGLIFLOZIN formulations in many countries for manyyears. Niksan pharmaceutical currently exports EMPAGLIFLOZINAPI and Formulation to countries like New Zealand, Jordan,Belgium, United Kingdom, Australia, Italy, Ireland, Hong Kong, Morocco,,Portugal, France, South Africa, Philippines, Malaysia, Singapore, Israel,Greece, Saudi Arabia, Egypt, Taiwan, Netherlands, South Korea, Switzerland,Algeria, Pakistan, Canada, Vietnam, United States, Germany, Brazil and manyother countries.

 

EMPAGLIFLOZIN is an oralantihyperglycemic agent of the SGLT2 (sodium-glucose co-transporter 2)inhibitor class, used to improve glycemic control in adults with type 2diabetes mellitus. It also reduces the risk of cardiovascular death in patientswith type 2 diabetes and established cardiovascular disease.

 

SYNONYSMS:Jardiance

 

IUPAC NAME: (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-D-glucitol

 

CAS NO:864070-44-0

 

FORMULA:C23H27ClO7

 

MOLECULAR MASS:  450.91 g/mol

 

STORAGE CONDITIONS:Store at 20°C to 25°C (68°F to 77°F).Protect from moisture and light. Store in a tightly closed container in a cool,dry place.

 

HOW TO USE:The usual startingdose is 10 mg orally once daily in the morning, with or without food. Based ontolerance and clinical response, the dose may be increased to 25 mg once daily.Always use as prescribed by the physician.

 

HOW EMPAGLIFLOZINWORKS:Empagliflozinworks by inhibiting SGLT2 in the proximal renal tubules. This reduces glucosereabsorption and increases urinary glucose excretion, thereby lowering bloodglucose levels. It also has beneficial effects on blood pressure and weight.

 

PHARMACOKINETICSOF EMPAGLIFLOZIN:Empagliflozin is rapidly absorbed after oral administration, with peakplasma concentrations occurring at 1.5 hours. It is 86% protein-bound,metabolized mainly by glucuronidation, and excreted via urine and feces.Terminal half-life is approximately 12.4 hours.

 

SIDE EFFECTSOF EMPAGLIFLOZIN:Urinarytract infections, Increased urination, Genital yeast infections, Dehydration, Hypotension, Increased cholesterol levels, Risk of ketoacidosis (rare), Acute kidney injury(rare)

 

PRECAUTIONS: Not for use inpatients with type 1 diabetes or diabetic ketoacidosis. Monitor renal functionbefore and during treatment. Use cautiously in patients on diuretics, thosewith low blood pressure, or history of urinary tract infections. Avoid inpregnancy unless necessary.

 

CDSCOAPPROVAL:Emphagliflozin Tablet 10/25 mg
07.05.15

 

 

FORMULATIONSAVAILABLE IN MARKET:

EMPAGLIFLOZIN 10 MG Tablets

EMPAGLIFLOZIN 25 MG Tablets

EMPAGLIFLOZIN + METFORMIN Tablets

EMPAGLIFLOZIN + LINAGLIPTIN Tablets

 

 

Note: Productprotected by valid patents are not offered for sale in countries where suchpatents are still valid and its liability is at Buyers Risk

 

REFERENCES:

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com 

https://cdscoonline.gov.in 

https://www.wikipedia.org/

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult